| | 1352608-82-2 Basic information More.. |
| Product Name: | EW-7197 | | Synonyms: | EW-7197;N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazole-2-methanamine;NOV-1301;TEW-7197;N-[[4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]methyl]-2-fluoroaniline;CPD3325-A5;N-(2-Fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo-[1,5-a]pyridin-6-yl-1H-imidazole;CPD3325 | | CAS: | 1352608-82-2 | | MF: | C22H18FN7 | | MW: | 399.42 | | EINECS: | | | Mol File: | 1352608-82-2.mol |  |
Use
EW-7197 is a novel ALK-5 kinase inhibitor as well as TGF- Type I Receptor Kinase Inhibitor. Study has shown that it can potently inhibit the breast to lung metastasis. Mice study has demonstrated that EW-7197 inhibited Smad/TGF signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice and 4T1 orthotopic-grafted mice. EW-7197 also inhibited the epithelial-to-mesenchymal transition (EMT) in both TGF-treated breast cancer cells and 4T1 orthotopic-grafted mice. Furthermore, EW-7197 enhanced cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice. It can also inhibit hepatic, renal, and pulmonary fibrosis by blocking TGF-/Smad and ROS signaling. Therefore, it is a potential antitumor reagent.
|
|
1352608-82-2
Recommend Suppliers |
|